Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
KW-040
- Development stage
- Phase 1
- Lead developer
- Kawin Technology
- Modality
- Vaccines & Immunotherapeutics, Recombinant Proteins and Enzymes
- Administration
- Subcutaneous
01
Overview
KW-040 is a therapeutic vaccine candidate developed by Beijing Kawin Technology for the treatment of chronic hepatitis B virus (HBV) infection. It is designed to stimulate the host's immune system to overcome the immune tolerance characteristic of chronic infection, aiming to achieve a functional cure, defined as sustained HBsAg loss. The drug is administered via subcutaneous injection and is currently being evaluated in Phase I clinical trials, specifically in adults with chronic HBV infection who are on stable nucleos(t)ide analogue (NA) therapy. KW-040 is part of a broader strategy to combine immunomodulators with antiviral agents to improve the rates of functional cure in the HBV patient population.
02
Targets
ASGPR (Asialoglycoprotein Receptor 1)Hepatitis B virus RNA transcripts encoding hepatitis B surface antigen (HBV HBsAg mRNA)AGO2 (Argonaute RISC catalytic component 2)
Beyond the preview
Go deeper on KW-040.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on KW-040.